



PART-I	Particulars	Standalone Quarter ended			Standalone year ended			Consolidated year ended	
		March 31, 2014	December 31, 2013	March 31, 2013	March 31, 2014	March 31, 2013	March 31, 2014	March 31, 2013	
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	
1	a) Income from Operations b) Other Operating Income Net Income from Operations	2,702.16 38.77 2,740.93	2,669.48 10.21 2,679.69	2,399.86 48.87 2,448.72	10,770.01 67.92 10,837.93	9,922.81 152.30 9,845.11	10,770.01 67.92 10,837.93	9,922.81 152.30 9,845.11	
2	a) Drugs and Consumables b) Employee Cost c) Professional Charges-Doctors d) Clinical Establishment Fee e) Net Depreciation and amortization f) Other Expenditure Total Expenditure	538.98 378.50 669.92 417.56 52.05 480.81 2,477.82	555.99 361.91 656.19 414.66 49.07 480.58 2,528.41	485.72 338.12 619.95 396.71 45.77 412.28 2,288.63	2,305.25 1,431.32 2,610.19 1,667.26 1,999.27 1,932.88 10,146.17	2,025.60 1,379.08 2,467.58 1,667.26 249.04 2,934.68 8,888.55	2,305.25 1,463.14 2,573.62 1,667.26 199.27 1,934.93 10,143.47	2,025.60 1,413.22 2,428.25 730.57 249.04 2,036.13 8,882.87	
3	Profit from operations before other Income, Interest & exceptional items (1-2)	293.11	181.28	160.19	691.66	956.56	694.36	952.30	
4	Other Income	159.15	167.88	138.85	661.43	278.20	690.25	278.20	
5	Profit before Interest & Exceptional Items (3 + 4)	432.26	349.16	299.04	1,353.09	1,236.76	1,384.61	1,230.50	
6	Finance Cost	9.98	13.06	7.90	46.73	80.04	45.73	80.04	
7	Profit from ordinary activities after Finance Cost but before Exceptional Items and Tax (5 - 6)	422.28	305.80	281.14	1,307.36	1,156.72	1,338.88	1,150.46	
8	Exceptional Items	-	-	-	-	353.28	-	392.77	
9	Interest Income (Refer Note 4 below)	-	-	-	-	353.28	-	392.77	
10	Profit from Ordinary Activities Before Tax	422.28	305.80	281.14	1,307.36	1,510.00	1,338.88	1,553.23	
11	Tax expense	143.51	104.06	93.88	451.58	492.58	461.32	505.94	
12	Net Profit from ordinary activities after Tax	278.77	201.74	187.26	855.78	1,017.42	877.56	1,047.29	
13	Extra Ordinary Items	-	-	-	-	3,900.54	-	4,347.83	
14	Profit on Sale of Clinical Establishment Business (Net of Tax expenses of Rs. 839.51 Lakhs) (Refer note 5 and 6 below)	278.77	201.74	187.26	855.78	4,317.96	877.56	4,347.83	
15	Net Profit after tax	278.77	201.74	187.26	855.78	4,317.96	877.56	4,347.83	
16	Paid up Equity Share Capital (Face Value Rs:10 each)	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95	
17	Reserves excluding Revaluation Reserves	1,860.95	1,860.95	1,860.95	6,561.96	5,814.97	6,620.07	6,951.31	
18	Earnings Per Share (EPS) - Basic (Rs.)	1.50	1.08	1.01	4.60	5.47	4.72	5.63	
19	- Before Extraordinary Items	1.50	1.08	0.81	4.60	23.20	4.72	23.36	
20	- After Extraordinary Items	1.50	1.08	1.00	4.50	5.46	4.72	5.62	
21	Earnings Per Share (EPS) - Diluted (Rs.)	1.50	1.08	0.81	4.50	23.18	4.72	23.32	
22	- Before Extraordinary Items	1.50	1.08	1.00	4.50	5.46	4.72	5.62	
23	- After Extraordinary Items	1.50	1.08	0.81	4.50	23.18	4.72	23.32	
<b>PART-II</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>A</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>1</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>PARTICULARS OF SHARE HOLDINGS</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>Public Shareholding</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
- Number of Shares		68,41,857	68,41,857	68,41,857	68,41,857	68,41,857	68,41,857	68,41,857	
- Percentage of shareholding		36.80%	36.80%	36.80%	36.80%	36.80%	36.80%	36.80%	
<b>2</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>Promoters and promoters group Shareholding</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
a) Pledged / Encumbered		NIL	NIL	NIL	NIL	NIL	NIL	NIL	
- No. of Shares		-	-	-	-	-	-	-	
- % of Shares (as a % of total shareholding of promoter and promoter group)		-	-	-	-	-	-	-	
b) Non-Encumbered		-	-	-	-	-	-	-	
- No. of Shares		1,17,52,402	1,17,52,402	1,17,52,402	1,17,52,402	1,17,52,402	1,17,52,402	1,17,52,402	
- % of Shares (as a % of total shareholding of promoter and promoter group)		100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
- % of Shares (as a % of total share capital of the company)		63.20%	63.20%	63.20%	63.20%	63.20%	63.20%	63.20%	
<b>B</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
<b>INVESTOR COMPLAINTS</b>		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Particulars		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Quarter ended March 31, 2014		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Pending at the beginning of the quarter		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Received during the quarter		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Disposed off during the quarter		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	
Remaining unresolved at the end of the quarter		[Not Annualised]		[Not Annualised]		[Not Annualised]		[Annualised]	



**NOTES:**

1	STATEMENT OF ASSETS AND LIABILITIES	Particulars	Standalone		Consolidated	
			As at March 31, 2014 (Audited)	As at March 31, 2013 (Audited)	As at March 31, 2014 (Audited)	As at March 31, 2013 (Audited)
		<b>I. EQUITY AND LIABILITIES</b>				
		Shareholders' funds				
		Share capital	8,422.91	7,675.92	8,481.02	7,712.26
		Reserves and surplus	1,960.95	1,860.95	1,960.95	1,860.95
			6,561.86	5,814.97	6,620.07	5,851.31
		Non-current liabilities				
		Deferred tax liabilities (net)	74.26	63.01	74.26	63.01
		Long term provisions	-	63.01	-	63.01
		Current liabilities	1,575.05	1,241.30	1,594.51	1,306.58
		Trade payables	1,028.55	865.88	1,030.64	867.41
		Other current liabilities	377.10	234.77	392.45	286.75
		Short-term provisions	169.39	120.57	171.42	122.42
		<b>Total</b>	<b>10,072.22</b>	<b>8,980.23</b>	<b>10,145.79</b>	<b>9,081.85</b>
		<b>II. ASSETS</b>				
		Non-current assets				
		Tangible assets	1,844.06	1,752.51	1,954.10	1,816.07
		Intangible assets	1,743.33	1,728.04	1,743.33	1,728.04
		Capital work in progress	19.83	8.87	19.83	8.87
		Non-current investments	64.23	-	64.23	-
		Deferred tax asset	5.00	5.00	-	-
		Long term loans and advances	-	10.60	0.96	0.71
		Current assets	11.67	10.60	125.75	78.45
		Inventories	8,228.16	7,227.72	8,195.69	7,265.78
		Trade receivables	26.53	39.43	26.53	39.43
		Cash and cash equivalents	390.48	320.65	390.48	320.65
		Short term loans and advances	1,014.87	292.22	1,016.31	300.50
		Other current assets	6,308.78	5,661.67	6,268.81	5,742.55
		<b>Total</b>	<b>10,072.22</b>	<b>8,980.23</b>	<b>10,145.79</b>	<b>9,081.85</b>

- 2 The above Audited Financial results have been reviewed by the Audit, Risk and Controls Committee, approved and taken on record by the Board of Directors in their meeting held on April 28, 2014.
- 3 The Company operates in one reportable segment in terms of Accounting Standard 17.
- 4 Interest Income aggregating Rs. 353.28 lakhs during the previous year ended March 31, 2013 earned on Inter-corporate deposit placed out of advance money received from Fortis Health Management Limited (FHML) towards sale of Clinical Establishment Business\* (CEB) upto October 16, 2012, being the effective date of transfer of the CEB has been disclosed as an exceptional item and the related interest income aggregating to Rs.255.37 lakhs for the year pertaining to the period subsequent to October 16, 2012 has been included as a part of other income.
- 5 During the year ended March 2013, the company had completed the sale of its Clinical Establishment Business to Fortis Health Management Limited (FHML) (collectively, 'the parties') pursuant to the Business Transfer Agreement (BTA) dated August 27, 2012. Accordingly the net assets of Rs.2,306.93 lakhs of Clinical Establishment business had been transferred as a going concern on a slump sale basis effective October 17, 2012 for an aggregate consideration of Rs.7,000 lakhs. The net profit aggregating Rs.3,300.54 lakhs (net of tax expense- Rs.839.51 lakhs) arising from the sale of the said business has been disclosed as an 'extraordinary item'.
- 6 Extraordinary expense in the quarter ended March 31, 2013 of Rs. 37.03 lakhs (net of tax benefits- Rs.10.22 lakhs) represents additional stamp duty cost incurred on the transfer of land in respect of the sale of CEB.
- 7 During the current year, the board has declared an Interim Dividend of 50 paise per share in its meeting held on August 30, 2013.
- 8 The amount for the quarter ended March 31, 2014 have been derived as a balancing figure between the amounts as per the annual audited accounts and the year to date results upto December 31, 2013.
- 9 Previous period figures have been regrouped, wherever considered necessary.



By Order of the Board  
 For and on Behalf of Board of Directors  
 V.Vijayarathna  
 Whole Time Director